PDS Biotechnology (NASDAQ:PDSB) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

PDS Biotechnology (NASDAQ:PDSB – Get Free Report) released its earnings results on Friday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02), FiscalAI reports.

PDS Biotechnology Stock Performance

PDS Biotechnology stock traded down $0.11 during mid-day trading on Friday, hitting $0.87. The company had a trading volume of 5,925,934 shares, compared to its average volume of 5,962,397. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. PDS Biotechnology has a 12-month low of $0.20 and a 12-month high of $1.79. The company’s fifty day moving average is $0.99 and its 200-day moving average is $0.84. The company has a market capitalization of $48.84 million, a price-to-earnings ratio of -1.36 and a beta of 1.16.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Monday, October 5th. HC Wainwright reaffirmed a “buy” rating on shares of PDS Biotechnology in a report on Wednesday, August 26th. B. Riley Financial reiterated a “buy” rating and issued a $4.00 price objective (up from $3.00) on shares of PDS Biotechnology in a research note on Thursday, October 29th. Finally, Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, September 28th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.50.

Get Our Latest Stock Report on PDS Biotechnology

PDS Biotechnology Company Profile

(Get Free Report)

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing immunotherapies designed to stimulate the immune system to fight cancer. The company’s research focuses on treatments for HPV-associated cancers and other solid tumors. Its pipeline includes PDS0101, an investigational immunotherapy targeting cancers associated with human papillomavirus 16 (HPV16). The candidate uses the company’s Versamune platform and is being studied in clinical trials, including in combination with other cancer treatments.

Read More

Earnings History for PDS Biotechnology (NASDAQ:PDSB)

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.